20
Participants
Start Date
February 8, 2001
Primary Completion Date
January 12, 2008
Study Completion Date
January 12, 2008
Myeloma Immunoglobulin Idiotype Vaccine
3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
Bortezomib
Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
Cyclophosphamide
Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)
Cyclosporine
Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
Doxorubicin hydrochloride
Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
Etoposide
Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3
Fludarabine phosphate
Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )
Prednisone
60 mg/m\^2 day 1-4
Vincristine Sulfate
Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3
Methotrexate
Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
GMCSF (granulocyte macrophage colony stimulating factor)
250 mcg/m\^2 subcutaneously every day, days 1-4
GCSF (granulocyte colony stimulating factor)
10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) \> 1000/ul x 2 days
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Cancer Institute (NCI)
NIH